Skip to content

Depression research published in 2024

Page 12 of 26: studies 221 to 240 of 512, newest first. Back to the depression overview

Studies

Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study.

Psychopharmacology July 1, 2024 Nathaniel A. Shanok, Sabrina Muzac, Leah Brown et al. 7 citations

Major Depressive Disorder (MDD) is a pervasive psychiatric condition effecting approximately 21 million adults in the U.S. (8.4%). An estimated 30-60% of patients are resistant to traditional treatment approaches (medications and talk-therapy), alluding to the need for additional options. Two promising treatment modalities include transcranial magnetic stimulation (TMS) and ketamine infusions;...

Implementation of a ketamine programme for treatment-resistant depression in the public health system: Lessons from the first Australian public hospital clinic.

Australian & New Zealand Journal of Psychiatry July 1, 2024 Nicollette Lr Thornton, Dean J Wright, Nick Glozier 5 citations

One could argue that we are living through a period of innovation and change in psychiatry unlike that seen before, with repurposed medications emerging as novel treatments. However, despite evidence of enhanced clinical outcomes and potential medium-term savings, delivering these promising interventions is resource-intensive and perceived as difficult in the public sector. Consequently, they...

DOI: 10.1177/00048674241237094 (opens in new tab) Full text (opens in new tab) Implementation Public hospital Ketamine therapy Mental health treatment +3

Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.

Journal of Affective Disorders July 1, 2024 Ashok Seshadri, Larry J. Prokop, Balwinder Singh 50 citations

Intravenous (IV) racemic ketamine and intranasal (IN) esketamine have demonstrated rapid antidepressant effects in treatment-resistant depression (TRD). This systematic review aims to evaluate the efficacy and safety of ketamine and esketamine at various dosages for depression. We included randomized controlled trials (RCTs) with parallel group dose comparison of ketamine and esketamine for...

Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.

Journal of Affective Disorders July 1, 2024 Cameron N Calder, Angela T H Kwan, Kayla M Teopiz et al. 31 citations

Ketamine has been established as efficacious in adults living with Treatment-resistant Depression (TRD). Toward providing a quantifiable estimate of the clinical meaningfulness of the therapeutic benefit of ketamine, herein, we conduct a systematic review that aims to report the Number Needed to Treat (NNT) and the Number Needed to Harm (NNH). This systematic review searched Embase,...

Subcutaneous ketamine reduces suicide risk and improves functioning in depression: A proof-of-concept study.

Psychiatry Research July 1, 2024 Ana Paula Anzolin, Daniel Prates Baldez, Bruno Braga Montezano et al. 2 citations

This investigation explores the efficacy of subcutaneous ketamine for mitigating depressive symptoms and suicidal ideation, addressing a crucial need for rapid-onset treatments in severe depression cases. It introduces an innovative approach to administering an NMDA receptor antagonist, significantly advancing psychopharmacological methods for treating suicidal behaviors as distinct entities,...

DOI: 10.1016/j.psychres.2024.115915 (opens in new tab) Full text (opens in new tab) C-ssrs Suicidal ideation Mental health treatment Depression therapy +3

Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression.

Biological Psychiatry Global Open Science July 1, 2024 Julia Aepfelbacher, Benjamin Panny, Rebecca B Price 13 citations

Ketamine, an NMDA receptor antagonist, provides rapid antidepressant effects. Although much research has focused on neural and molecular mechanisms of action, it is critical to also consider psychological mechanisms that may contribute to its therapeutic efficacy. The construct of an awe-inducing experience, which is a well-validated psychological phenomenon tied to emotional well-being, had...

DOI: 10.1016/j.bpsgos.2024.100316 (opens in new tab) Full text (opens in new tab) Mediation Mediator Psychological Ketamine therapy +4

Ketamine and electroconvulsive therapy for severe depression: A network meta-analysis of efficacy and safety.

Journal of Psychiatric Research July 1, 2024 Yecun Liu, Jiguo Yang, Yuanxiang Liu 8 citations

Ketamine, electroconvulsive therapy (ECT), and their combination are effective for treating severe depression, but few large-scale studies have compared these. We searched databases for randomized controlled trials (RCTs) using ketamine, ECT, ketamine + ECT, or placebo for severe depression. Standardized measures were efficacy outcomes. Risk of bias was assessed. Stata and ADDIS were used for...

DOI: 10.1016/j.jpsychires.2024.05.022 (opens in new tab) Full text (opens in new tab) Ketamine Electroconvulsive therapy Network meta-analysis Severe depression +5

Efficacy of addition of the anti-inflammatory, IV glutathione to standard ketamine IV therapy in major depressive disorder.

Psychiatry Research July 1, 2024 Ladan Eshkevari, Michelle Sales, Christina Collins et al. 3 citations

Ketamine, a N-methyl-D-aspartate (NMDA) antagonist, is used for treatment-resistant depression (TRD). Recent studies have shown that there are increased levels of pro-inflammatory cytokines in individuals with major depressive disorder (MDD) and those with higher levels of oxidative stress markers have a decreased or null response to conventional antidepressants. Glutathione (GSH) as an...

Efficacy and safety of peri-partum Esketamine for prevention of post-partum depression in women undergoing caesarian section: A meta-analysis and systematic review of randomized controlled trials.

Asian Journal of Psychiatry July 1, 2024 Muhammad Anas Nayyer, Suchna Meeral Khan, Mohammad Umer et al. 14 citations

Postpartum depression (PPD) is a psychiatric condition affecting women post-childbirth. Medication combined with psychotherapy, is the current protocol for its treatment. A meta-analysis was conducted using RevMan 5.4 to explore the efficacy and safety of peri-partum administration of esketamine for preventing PPD. After searching several databases to retrieve the relevant RCTs, seven were...

DOI: 10.1016/j.ajp.2024.104090 (opens in new tab) Full text (opens in new tab) Esketamine Meta-analysis Postnatal depression Postpartum depression +1

The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms.

Journal of Psychopharmacology July 1, 2024 Mariusz Papp, Piotr Gruca, Ewa Litwa et al. 15 citations

The highly selective 5-HT1A serotonin receptor "biased" agonists NLX-101 and NLX-204 display, like ketamine, potent and efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model with systemic (i.p.) administration. They rapidly (within 1 day) reverse anhedonia (i.e., CMS-induced sucrose consumption deficit), attenuate working memory deficit (novel object...

Beyond therapeutic potential: a systematic investigation of ketamine misuse in patients with depressive disorders.

Discover Mental Health July 1, 2024 Keshav Juneja, Sabah Afroze, Zeel Goti et al. 6 citations

Ketamine, a pharmacological agent that acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, has garnered considerable interest because of its notable and expeditious antidepressant properties observed in individuals diagnosed with major depressive disorder (MDD) who exhibit resistance to conventional therapeutic interventions. A comprehensive and rigorous systematic review was...

Combination of Transcranial Magnetic Stimulation and Ketamine in Treatment-Resistant Depression: A Systematic Review.

Cureus July 1, 2024 Oluwatosin O Arubuolawe, Ibrahim L Folorunsho, Adeniyi K Busari et al. 2 citations

Treatment-resistant depression (TRD) is a significant challenge in psychiatric practice, affecting a substantial proportion of patients with major depressive disorder (MDD). Traditional treatment modalities often fall short, necessitating the exploration of alternative therapies. This literature review examines the combined use of Transcranial Magnetic Stimulation (TMS) and ketamine in treating...

DOI: 10.7759/cureus.64712 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression trd Ketamine therapy Depression treatments Mental health interventions

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.

Nature Medicine July 1, 2024 Paul Glue, Colleen Loo, Johnson Fam et al. 60 citations

Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of administration. In this phase 2 multicenter clinical trial, male and female adult patients with TRD and Montgomery-Asberg Depression...

The Role of Mindfulness-Based Therapies in Alleviating Anxiety and Depression among Chinese University Students

American Journal of Health Behavior June 30, 2024 Hua Zhang, Yingxue Wang

Objective: Over the years, the prevalence of mental health issues such as depression and anxiety is rapidly increasing, emphasizing the incorporation of effective mindfulness-based therapies to overcome such issues. Therefore, this study also focuses on the role of mindfulness-based therapies in alleviating anxiety and depression among Chinese university students. Method: For this purpose,...

The mental health of nursing students during the COVID-19 pandemic: Beneficial effects of mindfulness-based stress reduction.

Heliyon June 30, 2024 Fariba Eslamimoghadam, Zahra Abedini, Ashraf Khoramirad 7 citations

Following the COVID-19 global emergency, health students were faced with increased workloads, university closures, study interruptions, loss of peer support networks, and the challenges of volunteer work in hospitals. These factors caused health students to experience significant stress and anxiety, highlighting the necessity of psychological interventions for this group. Several studies have...

Polish standard of treatment with racemic ketamine for patients with depressive disorders developed by a Working Group appointed by the National Consultant in the field of psychiatry.

Psychiatria Polska June 30, 2024 Piotr Gałecki, Katarzyna Maria Bliźniewska-Kowalska, Wiesław Jerzy Cubała et al. 5 citations

The Polish standard of treatment with racemic ketamine for patients with depressive disorders was developed by a Working Group appointed by the National Consultant in the field of psychiatry. Despite the wide range of available medications, as many as one-third of depressed patients do not respond to standard antidepressant treatment, raising the need for an ongoing search for new effective and...

A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope?

Children (Basel, Switzerland) June 29, 2024 Simone Pardossi, Andrea Fagiolini, Simona Scheggi et al. 12 citations

Treating depression in adolescents is a significant challenge, and major depressive disorder (MDD) with suicidal ideation and treatment-resistant depression (TRD) are common and potentially devastating to optimal psychological and physical development in this age group. Suicide is among the leading causes of youth mortality, and TRD occurs in up to 40% of adolescents with MDD. TRD involves...

Study protocol for the MIND-PD study: a randomized controlled trial to investigate clinical and biological effects of mindfulness-based cognitive therapy in people with Parkinson's disease.

BMC Neurology June 25, 2024 Anouk Van der Heide, Franziska Goltz, Nienke M De Vries et al. 5 citations

People with Parkinson's disease (PD) are very sensitive to the effects of stress. The prevalence of stress-related neuropsychiatric symptoms is high, and acute stress worsens motor symptoms. Animal studies suggest that chronic stress may accelerate disease progression, but evidence for this in humans is lacking. Mindfulness-based interventions (MBIs) train participants to focus on the present...

DOI: 10.1186/s12883-024-03736-7 (opens in new tab) Full text (opens in new tab) Anxiety Depression Disease progression Mindfulness-based cognitive therapy +2

Is decreasing problematic mobile phone use a pathway for alleviating adolescent depression and sleep disorders? A randomized controlled trial testing the effectiveness of an eight-session mindfulness-based intervention.

Journal of Behavioral Addictions June 21, 2024 Qingqi Liu, Xiujuan Yang, Chenyan Zhang et al.

Objective: The present study aimed to evaluate the efficacy of a mindfulness-based cognitive therapy (MBCT) intervention in reducing problematic mobile phone use, depression, and sleep disorders among adolescents. Additionally, it sought to investigate whether the decrease in problematic mobile phone use acted as a mediator in the relationship between the MBCT intervention and adolescent...

Psychedelic 25H-NBOMe attenuates post-sepsis depression in rats.

Neuroscience Letters June 21, 2024 Barbara G Ferri, Cintia O De Novais, Viviana C T Rojas et al. 3 citations

Sepsis-associated encephalopathy, which manifests in severe cognitive and depressive symptoms, is directly linked to neuroinflammation. Our study investigates the efficacy of 25H-NBOMe, a phenethylamine, in alleviating these symptoms, potentially offering an innovative treatment for post-sepsis depression. Wistar rats, weighing between 250-300 g, were subjected to cecal ligation and puncture...

DOI: 10.1016/j.neulet.2024.137845 (opens in new tab) Full text (opens in new tab) Animal models Forced swimming test Long-term sequelae Neuroinflammation +2